View clinical trials related to Graft-versus-host Disease (GVHD).
Filter by:To provide ruxolitinib through an expanded access to treat a single patient with cGVHD
To provide ruxolitinib through an expanded access program for the treatment of graft-versus-host disease (GVHD) in United States to patients who are ineligible or unable to participate in any actively enrolling Incyte-sponsored clinical studies for ruxolitinib in the treatment of GVHD.